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ABSTRACT
Background Therapy related myeloid neoplasms (t-MNs)
are complex diseases originating from an interplay
between exogenous toxicities and a susceptible
organism. It has been hypothesised that in a subset of
cases t-MNs develop in the context of hereditary cancer
predisposition syndromes.
Methods The study systematically evaluated pedigrees
of patients with t-MNs for cancer incidences and the
possibility of a hereditary cancer predisposition
syndrome. In addition, mutational analyses were
performed using constitutional DNA from index patients,
and deleterious heterozygous germline mutations were
assessed for loss of heterozygosity in sorted leukaemic
cells by single nucleotide polymorphism array.
Results A nuclear pedigree was obtained in 51/53
patients with t-MNs resulting in a total of 828 individuals
analysed. With a standardised incidence ratio of 1.03
(95% CI 0.74 to 1.39), the tumour incidence of first-
degree relatives was not increased. However, six
pedigrees were suggestive for a hereditary breast and
ovarian cancer syndrome, three of a Li-Fraumeni like
syndrome, and three index patients showed multiple
primary neoplasms. Mutational analysis revealed two
BRCA1 (c.3112G/T, c.5251C/T), one BRCA2
(c.4027A/G), two BARD1 (C557S) and four TP53
germline mutations (g.18508_18761delinsGCC,
c.847C/T, c.845_848dupGGCG, c.1146delA) in nine of
53 (17%) index patients with t-MNs. Loss of
heterozygosity in leukaemic cells was demonstrated for
the BRCA1c.3112G/T and TP53c.845_848dupGGCG
mutations, respectively.
Conclusion It is concluded that a proportion of patients
with t-MNs carry cancer susceptibility mutations which
are likely to contribute to therapy related
leukaemogenesis.
INTRODUCTION
Therapy related myeloid neoplasms (t-MNs)
constitute a distinct clinical syndrome including
therapy related acute myeloid leukaemia (t-AML),
myelodysplastic syndrome (t-MDS), and myelo-
dysplastic/myeloproliferative neoplasm (t-MDS/
MPN).1 2 These secondary diseases are mainly
observed after cytotoxic treatments for a malig-
nancy, but occur also after immunosuppressive
medication for autoimmune disorders or following
solid organ transplantation.3 4 The prognosis of
patients with t-MNs is dismal and allogeneic
haematopoietic stem cell transplantation (HSCT)
remains the only curative approach for the majority
of them.5 6 t-MNs are regarded as complex diseases
and previously published data on genetic predis-
position to t-MNs pointed to an interactive effect
of different single nucleotide polymorphisms
(SNPs) in pathways that mediate carcinogen
detoxification, proliferation, DNA repair, and
apoptosis.7 8 The demonstration of increased
familial tumour risk in patients with AML
following a primary neoplasm further supported
the concept of genetic susceptibility to t-MNs.9 10
Nevertheless, so far the prevalence of dominant
cancer susceptibility gene mutations in patients
with t-MNs has not been systematically assessed.
We therefore addressed the question of whether
t-MNs may also develop in the context of
hereditary cancer predisposition syndromes.
METHODS
Patients
From February 1997 to December 2010, 69 patients
with t-MNs were treated at the Divisions of
Hematology and Paediatric Hematology and
Oncology, Medical University of Graz, Austria,
which are tertiary cancer centres for a population of
about 1.5 million people. Of those, 53 patients
developed t-MNs after a primary malignant
disorder and were included in this study. Diagnosis
and classification of t-MNs were made according to
standard criteria.1 11
Pedigree analyses
Personal and telephone interviews were conducted
with index patients and/or their relatives to retrieve
the following information: (1) history of previous
illnesses of the index patient including cancer, age at
cancer diagnosis, date of diagnosis, and institution
at which the diagnosis and cancer treatment were
performed; (2) cancer history of family members. If
a malignancy was identified in a relative, the same
information was sought as for the index patient. To
allow standardised evaluation, a nuclear pedigree
according to Lynch et al was obtained that included
information on the patient’s siblings, progeny and
both parents (first-degree relatives) as well as
maternal and paternal aunts and uncles and both
sets of grandparents (second-degree relatives).12 We
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attempted to confirm each cancer diagnosis through pathology
reports from a medical database linking the university clinic with
referral hospitals, as well as medical reports requested from non-
affiliated hospitals and family physicians. In ambiguous cases,
tissue specimens were re-evaluated by pathologists experienced
in the diagnosis of neoplastic diseases. The accuracy of correctly
reporting cancer diagnoses by family members was evaluated
according to previous reports.13
Cancer incidence in first-degree relatives of patients with
therapy related myeloid neoplasms
To explore whether the incidence of malignancies was increased in
families of t-MN patients, we calculated the expected number of
cancer cases among first-degree relatives.14 This number was
obtained by multiplying the person-years for sex and 5-year-age
groups by corresponding age and sex specific incidence rates using
data from the tumour registry of the Austrian province Tyrol as
standard.15 Person-years at risk were accumulated for each first-
degree relative, beginning with the date of birth and ending either
with the date of diagnosis of the first malignancy, date of death,
or 31 December 2010. The standardised incidence ratio (SIR) was
calculated as the ratio of observed to expected number of cases,
a 95% CI assuming a Poisson distribution is given.
Mutational analyses
All index patients and pedigrees fulfilling one of the current
clinical classification criteria for the Li-Fraumeni/Li-Fraumeni-
like syndrome (LFS/LFL)16e19 as well as index patients with
multiple primary tumours were tested for TP53 germline
mutations. To identify patients suspicious of hereditary breast
and ovarian cancer syndrome (HBOCS), guidelines of the US
Preventive Services Task Force were implemented.20 We tested
every patient with a >10% probability of carrying germline
mutations in the BRCA genes.21 22 Following a hierarchical
order, patients tested negative for BRCA1/2 germline mutations
were evaluated for mutations in TP53 as well as for the BARD1
C557S and CHEK2 1100delC alleles.
Genomic DNA was isolated from cultured fibroblasts from
index patients using the QIAamp DNAMini Kit (Qiagen, Hilden,
Germany).23 Mutations were confirmed with DNA from
different tissues of the same individual. In patients harbouring
heterozygous germline mutations, leukaemic cells were analysed
for loss of the wild-type allele. CD34+ cells were separated from
diagnostic blood or bone marrow specimens using the magnetic
activated cell sorting CD34 MicroBead Kit together with MS
Columns and MiniMACS Separator (all Miltenyi Biotec, Bergisch
Gladbach, Germany). Purity of CD34+ cells was assessed by flow
cytometry with a FACSCalibur (BD, FranklinLakes, New Jersey,
USA). In case of homozygosity of the mutant allele, copy
number variation analysis and heterozygosity mapping were
performed using Affymetrix human genome-wide SNP 6.0 arrays
(Affymetrix, High Wycombe, UK) to distinguish between loss of
heterozygosity (LOH) and uniparental disomy as previously
described.24
Screening for BRCA1/2 germline mutations in HBOCS
patients was performed by Sanger sequencing as previously
described.25 Briefly, all BRCA1/2 exons as well as surrounding
intronic sequences were directly sequenced using an ABI3100
automated sequencer (Applied Biosystems, Foster City, Cali-
fornia, USA). Genetic variants were designated in accordance
with the BIC database (http://research.nhgri.nih.gov/bic/). To
screen for large genomic rearrangements (LGRs), multiplex
ligation dependent probe amplification (MLPA) analysis was
performed using the Salsa MLPA P002-B1 and P045-B1 kits,
respectively, according to the manufacturer ’s instructions (MRC
Holland, Amsterdam, The Netherlands). With respect to the
TP53 gene, coding exons 2 to 11 including splice sites were
amplified by PCR and analysed by direct Sanger sequencing on
an ABI3730 (Applied Biosystems) using oligonucleotides previ-
ously described by the IARC TP53 database (http://www-p53.
iarc.fr/). MLPA for detection of LGRs was conducted using the
Salsa MLPA kit P056 TP53 (MRC Holland). This kit also incor-
porates a specific probe for detection of the CHEK2 1100delC
mutation. In the case of BARD1, mutational analysis was focused
on the C557S allele by PCR and direct sequencing. All primer
sequences are available upon request. All variants were also
compared with the data from COSMIC (http://www.sanger.ac.
uk/genetics/CGP/cosmic), HGDM (http://www.hgmd.cf.ac.uk),
the 1000 Genomes Project (http://www.1000genomes.org), and
dbSNP131 to determine their pathogenic relevance. Nonsense
mutations were regarded as potentially pathogenic but addi-
tionally tested for functional consequences using MutationTaster
(http://www.mutationtaster.org). Non-synonymous variations
were also tested with SIFT (http://sift.jcvi.org/) and PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/).
To assess the validity of this clinical approach described above,
all remaining index patients with available DNA specimens were









Primary neoplasms 63 (100)
Solid tumours 37 (59)
Breast cancer 18 (29)
Sarcoma 6 (10)
Colon cancer 2 (3)
Other 11 (17)
Haematological malignancies 26 (41)
Non-Hodgkin’s lymphoma 16 (25)
Acute myeloid leukaemia 4 (6)
Acute lymphoblastic leukaemia 2 (3)
Hodgkin’s disease 2 (3)
Plasma cell myeloma 2 (3)
Primary cytotoxic treatments
Alkylating agents 29 (55)
Topoisomerase II inhibitors 12 (23)
Antimetabolites 20 (38)










Progression t-MDS / t-AML 14 (61)
Median time, months 3
Range, months 1e31
ASCT, autologous haematopoietic stem cell transplantation; t-AML, therapy related acute
myeloid leukaemia; t-MDS, therapy related myelodysplastic syndrome; MPN,
myeloproliferative neoplasm.
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screened for TP53 germline mutations as described above.
Furthermore, all remaining t-MN patients with breast cancer as
primary malignancydirrespective of their family historydwere
tested for BRCA1/2 germline mutations. Therefore, next gener-
ation sequencing was applied using the HaloPlex PCR target
enrichment system (Halo Genomics, Uppsala, Sweden). In brief,
patient DNAs were digested by a cocktail of restriction enzymes
and hybridised to BRCA1/2 specific probes incorporating Illu-
mina specific sequence motifs. Hybridised molecules were
captured with magnetic beads, subsequently amplified using
indexed primers, and finally sequenced with the MiSeq system
(Illumina, San Diego, California, USA). Unknown or pathogenic
variants were further verified by conventional Sanger
sequencing.
Immunohistochemical analysis of p53
Immunohistochemistry of p53 was performed on paraffin
embedded tissue with the IgG2b monoclonal mouse anti-human
antibody clone (M7001, DakoCytomation, Glostrup, Denmark)
according to the supplier ’s recommendations. The epitope
recognised by the antibody is located between N-terminal amino
acids 1 and 45 of the human p53 protein.26
RESULTS
Of the 53 t-MN patients studied, 49 were adults and four were
minors (table 1). A total of 63 primary malignancies were
diagnosed in these individuals with breast cancer (18/63, 29%),
and non-Hodgkin’s lymphoma (16/63, 25%) being the most
common. The 18 breast cancers were observed in 14 t-MN
patients; multiple primary malignancies were recorded in 10/53
(19%) individuals. Cytogenetic analysis of leukaemic cells
obtained at t-MN diagnosis revealed clonal aberrations in 42/50
available specimens (84%) (supplementary table 1).
A nuclear pedigree was obtained in 51/53 patients with
t-MNs. These pedigrees consisted of a total of 828 individuals
with 327 first- and 450 second-degree relatives. The median
number of family members per pedigree was 16 (range 10e25).
Personal interviews revealed a total of 218 malignancies: 111 in
index patients, 46 in first- and 61 in second-degree relatives. One
hundred and sixty malignancies could be confirmed by medical
reports, death certificates or re-evaluation, resulting in a 73%
accuracy of correctly reported cancer diagnoses. For the calcu-
lation of SIR, data from 41 first-degree relatives with
a neoplastic disease were used. With 39.9 expected cases, a SIR of
1.03 (95% CI 0.74 to 1.39) was obtained based on data from the
tumour registry Tyrol.
Among 51 patients with known pedigrees, nine (18%) were
suspicious of a hereditary cancer predisposition syndrome: six
(12%) of an HBOCS and three (6%) of an LFS/LFL. Moreover,
three index patients (6%) showed at least two primary benign
and/or malignant tumours in addition to breast cancer raising
the suspicion of LFL. Therefore, a total of 12 patients (24%) were
initially tested for germline mutations in cancer associated
genes. Germline mutations were found in six patients with
t-MNs (12%) by this clinically oriented approach: two with
a BRCA1 and three with a TP53mutation as well as one with the
BARD1 C557S variant. To assess the validity of this approach,
TP53 mutation screening was extended to 37 remaining t-MN
index patients with available DNA samples. Additionally, all
remaining untested breast cancer index patients were analysed
for BRCA1/2 germline mutations as well as the BARD1 C577S
variant. We also included two more t-MN patients with
unknown family history, one with breast cancer and one minor
with a sarcoma. Three additional germline mutations could be
identified, one each in BRCA2, BARD1, and TP53. Overall, we
tested 13 patients for BRCA1/2, 49 patients for TP53 as well as
CHEK2 1100delC, and 11 patients for the BARD1 C577S variant,
and identified a total of two BRCA1, one BRCA2, two BARD1,
and four TP53 germline mutations (9/53, 17%) (table 2).
Patient UPN 5869 developed t-MDS with a complex karyotype
5 years after chemotherapy for ovarian cancer at the age of
56 years. Her pedigree showed multiple breast and gastric
cancers. A heterozygous, nonsense c.3112G/T BRCA1mutation
was detected in constitutional DNA. Leukaemic cells revealed
hemizygosity of the mutation due to loss of the wild-type allele
(figure 1A). In patient UPN 5824, t-MDS with monosomy 7 was
diagnosed at the age of 35 years. She suffered from bilateral breast
cancer at the age of 28 and 33 years, respectively, and was treated
with surgery, ionising radiation, and multiple cycles of cytotoxic
Table 2 Germline mutations identified in patients with therapy related myeloid neoplasms




Truncating mutation (NMD), clinically
important (BIC)




Truncating mutation (NMD), clinically
important (BIC)
HBOCS Multiple entries in BIC
5298 BRCA2 c.4027A>G
p.K1343E
Benign (PP2); tolerant (SIFT); polymorphism,








Reduced capability of growth suppression
and apoptosis











Truncating mutation (NMD), predicted disease
causing (MT)
Multiple diverse neoplasms None
6144 TP53 c.1146delA
p.K382fs*40
Prolonged p53 (+27 AA), predicted disease
causing (MT)
Inconspicuous Somatic mutation in a gastric




Deleterious (TMD) Inconspicuous, identified
by comprehensive screening
Multiple entries in TMD and COSMIC
dbSNP build 131; NM_007294.3 (BRCA2); NG_017013.1, NM_000546.4 (TP53).
BIC, breast cancer information core database; EBV, Epstein-Barr virus; HBOCS, hereditary breast and ovarian cancer syndrome; LFL, Li-Fraumeni like syndrome; MT, MutationTaster; NMD,
nonsense mediated mRNA decay; PP2, PolyPhen-2; SIFT, Sorting Tolerant From Intolerant algorithm; TMD, IARC TP53 Mutation Database; UPN, unique patient number.
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drugs. Pedigree analysis demonstrated multiple neoplasms
including breast, ovarian, and lung cancer. A heterozygous,
nonsense c.5251C/T BRCA1 mutation was identified in both,
constitutional and leukaemic DNA (supplementary figure 1).
Patient UPN 5298 who also had a history of thyroid adenoma
received combined chemo- and radiotherapy for breast cancer at
the age of 62 and developed t-AML with trisomy 8 two years
later. Her family history included malignant melanoma and
metastatic cancer of unknown origin. Constitutional DNA and
DNA from unsorted leukaemic cells showed a BRCA2
c.4027A/G variant (supplementary figure 2). t-AML with
trisomy 8 developed in patient UPN 6387 following ionising
radiation for breast cancer. Pedigree analysis revealed HBOCS and
a heterozygous missense BARD1 C557S variant was identified in
constitutional and leukaemic DNA (supplementary figure 3).
A second patient (UPN 4353) with the same mutation was
identified by screening of those breast cancer patients not
included in the first approach. This individual received radio-
therapy for breast cancer at the age of 63 years and developed
t-AML at age 72. UPN 6371 was diagnosed with t-MDS with
a complex karyotype at the age of 54 years. Her history included
angiomyolipoma, enchondroma and breast cancer, the latter
treated with surgery and ionising radiation at the age of 50 years.
Pedigree analysis showed multiple diverse neoplasms in first- and
second-degree relatives. Constitutional DNA revealed a hetero-
zygous c.845_848dupGGCG TP53mutation and leukaemic DNA,
a hemizygous state due to loss of the wild-type allele (figure 1B).
A heterozygous LGR encompassing parts of TP53 intron 7 and
exon 8 was identified in the paediatric patient UPN 5650 by
MLPA and confirmed as g.18508_18761delinsGCC by direct
Figure 1 (A) Pedigree and mutational analysis of index patient UPN 5869. The pedigree indicates a hereditary breast and ovarian cancer syndrome.
Electropherograms illustrate the BRCA1 c.3112G/T mutation (arrow) as well as a nearby single nucleotide polymorphism (SNP) in DNA from
fibroblasts and CD34+ leukaemic cells. Both mutation and SNP became homozygous in the leukaemic clone. The SNP array reveals a copy number
state 1 and loss of heterozygosity (LOH) at the BRCA1 locus on chromosome 17q of CD34+ leukaemic blasts. (B) Pedigree and mutational analysis of
index patient UPN 6371. The pedigree is not specific for a certain syndrome. Electropherograms illustrate the TP53 c.845_848dupGGCG mutation in
germline as well as somatic DNA. SNP array shows copy number state 1 and LOH at the TP53 locus on chromosome 17p of CD34+ leukaemic cells.
Filled symbols, subjects with malignancies; open symbols, asymptomatic subjects; the arrow indicates the index patient; number within symbol
corresponds to the number of asymptomatic individuals. Red regions represent losses and violet regions LOH. BlaCa, bladder cancer; BrCa, breast
cancer; Ca, cancer of unknown origin; GaCa, gastric cancer; Leuk, leukaemia of unknown type; Pheo, pheochromocytoma; Plas, plasmacytoma; ProCa,
prostate cancer; UtCa, uterine cancer; y, age in years at diagnosis.
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sequencing (figure 2). She suffered from t-AML at the age of
7 years, 2.5 years after the commencement of combined chemo-
and radiotherapy for embryonal rhabdomyosarcoma. Her
leukaemia was cured by allogeneic HSCT but she eventually
developed a fibrosarcoma in the former radiation field at the age
of 10 years. Somatic homozygosity of the mutated allele could
be demonstrated in DNA from both sarcomas by PCR and these
neoplastic tissues were also negative for p53 immunostaining.
Her family history was negative for any cancer, suggesting a de
novo germline mutation.
Patient UPN 6144 suffered from t-AML following chemo-
therapy for breast cancer at the age of 78 years. She had a history
of cystadenoma of the ovary, uterine leiomyoma and renal
cancer; however, her pedigree was inconspicuous. DNA from
fibroblasts and leukaemic cells showed a heterozygous
c.1146delA TP53 mutation (supplementary figure 4).
Finally, patient UPN 7047 was identified as carrying the
deleterious R283C TP53 germline mutation which remained
heterozygous in DNA from blast cells (supplementary figure 5).
p53 immunohistochemistry was strongly positive in over
80% of leukaemic cells. He developed t-AML with a 7q dele-
tion as well as a colonic adenoma at the age of 67, both
2 years after radiation for primary prostate cancer. His family
history revealed a grandfather suffering from prostate cancer
as well.
In addition, 10 different SNPs in BRCA1 (seven non-
synonymous) and 15 in BRCA2 (six non-synonymous) were
detected in the 13 patients tested for BRCA1/2mutations. Forty-
two of 49 patients tested had the known TP53 P72R SNP, of
whom 20 (41%) were homozygous. No CHEK2 1100delC
mutation was found. Results are summarised in supplementary
tables 2e4. Surprisingly, the possibility of a hereditary cancer
predisposition syndrome was recognised by the caring physi-
cians in only one of the suspected 12 index patients at the time
of the primary malignancy. In this individual (UPN 5294),
a screen for germline mutations in the BRCA genes was negative.
DISCUSSION
In this study, we performed systematic pedigree and mutational
analyses on patients with t-MNs seen at a tertiary cancer centre.
A major goal was the identification of hereditary cancer predis-
position syndromes; we therefore focused on patients who
developed t-MNs after a primary malignant disorder. Impor-
tantly, this cohort is representative of t-MNs since demographic
data were comparable to published studies.3 4
Previous publications on pedigree analyses of patients with
secondary myeloid neoplasms pointed to an increased familial
risk. Although Ben-Yehuda et al reported a family history of
cancer in 55% of patients with t-MNs, no details are given on
exact incidence rates as the authors primarily focused on
molecular aspects of t-MNs.9 Pagana et al described a significant
increase of neoplastic diseases among first-degree relatives of
patients with secondary AML as compared to those with de novo
AML.10 The authors, however, did not restrict their analysis to
patients with AML following cytotoxic treatments but also
included patients whose primary malignancies were treated with
surgery only. In the cohort analysed here, the SIR of cancers
among first-degree relatives was not significantly increased when
compared to population based data from the tumour registry
Tyrol, an Austrian province with an almost identical ethnic
background. One explanation might be that an analysis of SIR
focuses on first-degree relatives. Our cohort, however, is
Figure 2 Mutational analysis of index patient UPN 5650 with a TP53 g.18508_18761delinsGCC germline mutation. (A) Multiplex ligation dependent
probe amplification (MLPA) analysis showing a reduced amplification signal of the TP53 exon 8 probe as compared with the other TP53 and control
probes. (B) Agarose gel electrophoresis of PCR products obtained from TP53 amplicons encompassing exons 7 to 9. Lane 1, wild-type amplicon whose
calculated size is 866 bp. Lane 2, whole blood DNA collected during remission showing a heterozygous pattern with an additional shorter PCR product.
Lane 3, DNA from embryonal rhabdomyosarcoma. Lane 4, DNA from fibrosarcoma showing the mutated amplicon only, indicating a homozygous state
and loss of the wild-type TP53 allele. Lane 5, negative control. (C) Immunohistochemistry of p53. Histologic specimens of therapy related acute
myeloid leukaemia (left) and fibrosarcoma (right) showing negative staining. (D) Direct sequencing of the mutated amplicon demonstrating the genomic
breakpoints of the TP53 LGR. TP53 reference: NG_017013.1.
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characterised by a high incidence of neoplasms in second- and
third-degree relatives as is shown for both BRCA1 mutation
carriers (figure 1A, supplementary figure 1). Another reason
might be the relatively small number of family members analysed
here. A more accurate evaluation of the familial cancer risk of
patients with t-MNs using registry data, however, is impossible
at present as t-MNs are not coded as a separate disease entity.
Based on pedigree data, we suspected a hereditary cancer
predisposition syndrome in 12 index patients and eventually
identified six clinically relevant germline mutations in genes
associated with DNA damage response. Interestingly, through
comprehensive screening, another three germline mutations
could be detected. The majority of mutations were found in
patients with breast cancer as the primary malignancy (6/14,
43%). Both BRCA1mutations identified are pathogenic and have
been described previously in the BIC database. Although they
have not been associated with the development of myeloid
malignancies so far, deregulated BRCA function is increasingly
recognised as contributing to myeloid leukaemogenesis. Germ-
line mutations in BRCA2dalso known as FANCD1dcause
Fanconi anaemia, a congenital disorder with high propensity for
the development of AML.29 Furthermore, reduced expression of
BRCA1 was reported in leukaemic specimens of cases with t-
AML.30 We identified the new BRCA2 K1343E variation by the
comprehensive mutational screening approach. This non-
synonymous variation was rated as SNP by computational
functional significance predictors; however, it is located between
the highly conserved domains BRC1 and BRC2 of BRCA2 which
are involved in RAD51 binding and essential for initiation of
homologous recombination at sites of DNA double-strand
breaks.31 SNPs and non-synonymous variants are common in
BRCA2 (supplementary table 3), but without further functional
evaluation it is difficult to distinguish between truly pathogenic
mutations and rare but harmless variants. Given the inconspic-
uous pedigree of patient UPN 5298, mediating predisposition to
HBOCS by K1343E seems unlikely. It nevertheless might
contribute to leukaemogenesis following cytotoxic stress, which
applies to all mutations found in this study.
BARD1 is a tumour suppressor which acts together or inde-
pendently of BRCA1 in mediating cell cycle regulation and DNA
repair in response to genotoxic stress.32 Repression of BARD1
decreases sensitivity to doxorubicin induced apoptosis, and
concomitant depletion of BRCA1 and BARD1 disturbs the G1/S
checkpoint arrest through lack of p53 phosphorylation following
irradiation.33 34 The BARD1 C557S variant has been described as
a susceptibility allele for BRCA1/2 negative hereditary breast
cancer, and clinical data are supported by functional studies
showing that this mutation mediates loss of growth suppression
and reduced apoptosis in vitro.27 35 To date, however, no asso-
ciation of BARD1 mutations with myeloid leukaemias has been
reported. TP53 germline mutations have been described before in
single cases of t-MNs. In the cohort studied here, TP53 germline
mutations are highly enriched (4/53, 8%), given an estimated
prevalence of 1:20000 in the general population.36 Three of these
mutations have not yet been reported in primary human
malignancies. The TP53 c.1146delA variant was described in two
cancer cell lines suggesting a possible role in immortalisation.28
This mutation elongates the p53 protein, leaving the trans-
activation domain intact, but results in a lysine to alanine
substitution at residue 382 and loss of the phosphorylation site
at serine 392dboth sites important for stabilisation of p53
following irradiation and other stimuli.37 38 Interestingly, patient
UPN 5650 with a TP53 germline LGR developed her second
sarcoma in a former radiation field, emphasising the risk of
therapy related oncogenesis in patients with the LFS.39 The
detection of LOH for the BRCA1 c.3112G/T and TP53
c.845_848dupGGCG mutations in leukaemic cells as well as
overexpression of p53 in blasts with heterozygous R283C
suggest that they contribute to leukaemogenesis. However,
functional studies which are underway will conclusively deter-
mine their exact role in the pathogenesis of these secondary
malignancies.
In conclusion, our study demonstrates that cancer predispo-
sition syndromes are prevalent in patients with t-MNs and can
be identified by conventional pedigree analysis as well as
systematic mutational screens. With respect to therapy related
myeloid leukaemogenesis, they may extend current knowledge
as germline mutations in cancer predisposition genes may also
contribute to these secondary disorders. Clinically, the detection
of such mutations has far reaching consequences for the
surveillance of both patients and their family members.
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